Hematologic Malignancy
Smoldering Multiple Myeloma
CI-CAN-00003983Explore in graph →
Hematologic34 active trials
- NCIt
- C7149
- MeSH
- D000075122
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003983Explore in graph →
Clinical trials
85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04920084 | A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | active not recruiting | N/A | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06183489 | Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma(ERASMM) | active not recruiting | Phase 2 | 50 | European Myeloma Network B.V.NETWORK | 4 | Sep 2, 2026 |
| clinicaltrials |
| NCT00114101 | Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | active not recruiting | Phase 3 | 460 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05831358 | Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program | active not recruiting | N/A | 201 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01169337 | Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 226 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT02603887 | Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01177527 | Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | active not recruiting | — | 656 | Dana-Farber Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05014646 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | active not recruiting | Phase 2 | 27 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02960555 | Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) | active not recruiting | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05955508 | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | active not recruiting | Phase 2 | 40 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03236428 | Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02886065 | A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | active not recruiting | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05767359 | CAR- PRISM (PRecision Intervention Smoldering Myeloma) | active not recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04850846 | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04370483 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 1 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04144387 | Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.(CARRISMM) | active not recruiting | N/A | 395 | Intergroupe Francophone du MyelomeNETWORK | 3 | Mar 6, 2024 | clinicaltrials |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant(ASCENT) | active not recruiting | Phase 2 | 87 | International Myeloma FoundationOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM(HO147SMM) | active not recruiting | Phase 2 | 58 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Nov 1, 2023 | clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials